Department of Cell and Cancer Biology, University of Toledo Health Science Campus, Toledo, OH 43614, USA.
Department of Chemistry and Biochemistry, University of Heidelberg, Tiffin, OH 44883, USA.
Cells. 2022 May 5;11(9):1559. doi: 10.3390/cells11091559.
Glioblastoma (GBM) is a progressive and lethal brain cancer. Malignant control of actin and microtubule cytoskeletal mechanics facilitates two major GBM therapeutic resistance strategies-diffuse invasion and tumor microtube network formation. Actin and microtubule reorganization is controlled by Rho-GTPases, which exert their effects through downstream effector protein activation, including Rho-associated kinases (ROCK) 1 and 2 and mammalian diaphanous-related (mDia) formins (mDia1, 2, and 3). Precise spatial and temporal balancing of the activity between these effectors dictates cell shape, adhesion turnover, and motility. Using small molecules targeting mDia, we demonstrated that global agonism (IMM02) was superior to antagonism (SMIFH2) as anti-invasion strategies in GBM spheroids. Here, we use -wild-type GBM patient-derived cell models and a novel semi-adherent in vitro system to investigate the relationship between ROCK and mDia in invasion and tumor microtube networks. IMM02-mediated mDia agonism disrupts invasion in GBM patient-derived spheroid models, in part by inducing mDia expression loss and tumor microtube network collapse. Pharmacological disruption of ROCK prevented invasive cell-body movement away from GBM spheres, yet induced ultralong, phenotypically abnormal tumor microtube formation. Simultaneously targeting mDia and ROCK did not enhance the anti-invasive/-tumor microtube effects of IMM02. Our data reveal that targeting mDia is a viable GBM anti-invasion/-tumor microtube networking strategy, while ROCK inhibition is contraindicated.
胶质母细胞瘤(GBM)是一种进行性和致命的脑癌。肌动蛋白和微管细胞骨架力学的恶性控制促进了 GBM 两种主要治疗耐药策略——弥散性浸润和肿瘤微管网络形成。肌动蛋白和微管的重组受 Rho-GTPases 控制,这些 GTPases 通过下游效应蛋白的激活发挥作用,包括 Rho 相关激酶(ROCK)1 和 2 以及哺乳动物 Dia 相关(mDia)形成蛋白(mDia1、2 和 3)。这些效应物之间的活性精确的时空平衡决定了细胞的形状、黏附周转率和运动性。使用靶向 mDia 的小分子,我们证明了全局激动剂(IMM02)在 GBM 球体中作为抗侵袭策略优于拮抗剂(SMIFH2)。在这里,我们使用 -野生型 GBM 患者来源的细胞模型和一种新的半黏附体外系统来研究 ROCK 和 mDia 在侵袭和肿瘤微管网络中的关系。IMM02 介导的 mDia 激动剂破坏 GBM 患者来源球体模型中的侵袭,部分原因是诱导 mDia 表达丧失和肿瘤微管网络崩溃。ROCK 的药理学破坏阻止了侵袭性细胞体从 GBM 球体上的运动,但诱导了超长的、表型异常的肿瘤微管形成。同时靶向 mDia 和 ROCK 并没有增强 IMM02 的抗侵袭/肿瘤微管作用。我们的数据表明,靶向 mDia 是一种可行的 GBM 抗侵袭/肿瘤微管网络形成策略,而 ROCK 抑制则相反。